Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00687505 · ClinicalTrials.gov registry record · Phase 1
Safety Study of FP-1039 To Treat Cancer
A Phase 1 study of Advanced Cancer, sponsored by Five Prime Therapeutics.
- Completed
- Registry status
- Phase 1
- Development phase
- 39
- Enrollment target
- 2
- Study locations
NCT00687505: Completed Phase 1 study of Advanced Cancer, sponsored by Five Prime Therapeutics.
NCT00687505 is a Phase 1 study of Advanced Cancer that has completed, run by Five Prime Therapeutics. The registered enrollment target is 39 participants, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (84% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00687505, a Phase 1 study of Advanced Cancer, has completed, sponsored by Five Prime Therapeutics.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 39 participants
- Enrollment target
- 2
- Study locations
Study Summary
The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
Conditions Studied
Interventions
- DRUG FP-1039
Study Locations (2)
Michigan
- Karmanos Cancer Institute - Detroit
Texas
- START (South Texas Accelerated Research Therapeutics) - San Antonio
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2008-07 |
| Est. Completion | 2011-06 |
| Phase | Phase 1 |
What the finished NCT00687505 record still lists
NCT00687505 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 39 participants, a relatively small participant target, below the 246-participant average among 122 other Advanced Cancer trials with a reported enrollment target (84% lower).
The record links to 1 condition, with Advanced Cancer appearing as the primary indexed condition, and to 1 intervention - of which FP-1039 is the first listed.
NCT00687505 reports a single indexed study location in Michigan, Texas.
Frequently Asked Questions
What is clinical trial NCT00687505 about?
NCT00687505 is a clinical study titled "Safety Study of FP-1039 To Treat Cancer". The primary purpose of this study is to evaluate the safety and tolerability of FP-1039, a new biologic treatment for cancer.
What is the current status of trial NCT00687505?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 39 participants. The study started on 2008-07. Estimated completion is 2011-06.
What conditions does trial NCT00687505 study?
This clinical trial studies the following conditions: Advanced Cancer.
What interventions are being tested in trial NCT00687505?
The interventions under investigation include: FP-1039 (DRUG).
Who is sponsoring clinical trial NCT00687505?
This trial is sponsored by Five Prime Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00687505 being conducted?
This trial has 2 study locations across Michigan, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Advanced Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00687505's enrollment target sits among peer trials
39 92nd of 122 higher than 30 of 122 other Advanced Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Advanced Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1b Trial of BMS-986504 in Combination With Olaparib in Patients With MTAP Loss
RECRUITING · Phase 1
-
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Antitumor Activity of ALK202 in Participants with Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study in Patients With Advanced Cancers
RECRUITING · Phase 1
-
A Study of MGC026 in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03465592 · 39 participants · Phase 1
Trial of Nivolumab Following Partially Human Leukocyte Antigen (HLA) Mismatched BMT in Children & Adults With Sarcoma
- NCT03961776 · 39 participants
Monitoring Treatment Response With On-board DWI During Neo-adjuvant Chemo-radiation for Rectal Cancer Using Magnetic Resonance-guided-radiotherapy Systems
- NCT04050280 · 39 participants · Phase 2
CLAG-GO for Patients With Persistent, Relapsed or Refractory AML
- NCT04190862 · 39 participants · Phase 1
E-CEL UVEC as an Adjunct Cell Therapy for Treatment of Anal Fistulas
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia